FERRER, Florent; TETU, Pauline; DOUSSET, Lea; LEBBE, Celeste; CICCOLINI, Joseph; COMBAREL, David; MEYER, Nicolas; PACI, Angelo; BOUCHET, Stephane

doi:10.1016/j.critrevonc.2024.104385

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

Langue

Article de revue

Ce document a été publié dans

Critical Reviews in Oncology/Hematology. 2024-08-01, vol. 200, p. 104385

Résumé en anglais

Real-life populations are more heterogeneous than those included in prospective clinical studies. In cancer patients, comorbidities and co-medications favor the appearance of severe adverse effects which can significantly impact quality of life and treatment effectiveness. Most of tyrosine kinase inhibitors (TKI) have been developed with flat oral dosing exposing patients to the risk of poor adherence due to side effects. Additionally, genetic or physiological factors, differences in diet, and drug-drug interactions can lead to inter-individual variability affecting treatment outcomes and increasing the risk of adverse events. Knowledge of the different factors of variability allows individualized patient management. This review examines the effects of adherence, food intake, and pharmaceutical form on the pharmacokinetics of oral TKI, as well as evaluating pharmacokinetics considerations improving TKI management. Concentration-effectiveness and concentration-toxicity data are presented for the selected TKI, and a simple therapeutic drug monitoring schema is outlined to help individualize dosing of oral TKI.< Réduire

Mots clés en anglais

Efficacy

Pharmacokinetics

Therapy management

Variability

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche